MedTrace Logo

Exposure Chamber Trial With Cat Immunotherapy

NCT00987909 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2010-08-18

No results posted yet for this study

Summary

The main purpose of this trial is to investigate if any of three different doses of cat hair immunotherapy is safe for treatment of cat allergic patients.

Conditions

  • Cat Allergy

Interventions

BIOLOGICAL

Specific allergen immunotherapy (placebo)

Drops for sublingual administration, 0 mcg (placebo), once daily administration for 16 weeks

BIOLOGICAL

Specific allergen immunotherapy

Drops for sublingual administration, 4.5 mcg Fel d1/day, once daily administration for 16 weeks.

BIOLOGICAL

Specific allergen immunotherapy

Drops for sublingual administration, 9.0 mcg Fel d1/day, once daily administration for 16 weeks

BIOLOGICAL

Specific allergen immunotherapy

Drops for sublingual administration, 18.0 mcg Fel d1/day, once daily administration for 16 weeks

Sponsors & Collaborators

  • Cetero Research, San Antonio

    collaborator NETWORK

  • ALK-Abelló A/S

    lead INDUSTRY

Principal Investigators

  • Deepen Patel, MD, CCFP · Cetero Research, San Antonio

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-03-31
Completion
2010-05-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00987909 on ClinicalTrials.gov